Imaging cancer using a novel PET agent targeting PSMA
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Malignant Tumors
This study is testing a new imaging agent to see if it can help better detect certain cancers, especially prostate cancer, in patients who have already had a PET scan.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05887687 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a new PET imaging agent, [68Ga]P3, which targets prostate-specific membrane antigen (PSMA) to enhance the diagnosis of various malignancies. PSMA is highly expressed in prostate cancer cells and certain tumor blood vessels, making it a promising target for imaging. The trial will involve patients with confirmed or suspected cancer who have undergone a recent 18F-FDG PET/CT scan. The goal is to evaluate the effectiveness of [68Ga]P3 in identifying high-expression PSMA malignancies.
Who should consider this trial
Good fit: Ideal candidates include adults with confirmed or suspected cancer who have recently undergone an 18F-FDG PET/CT scan.
Not a fit: Patients who are pregnant, lactating, or planning to become pregnant within six months will not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could lead to more accurate diagnoses and better-targeted treatments for patients with PSMA-expressing tumors.
How similar studies have performed: Other studies have shown promising results with PSMA-targeted imaging agents, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written informed consent Exclusion Criteria: Pregnant and lactating women; Female patients plan to become pregnant within 6 months.
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xing Yang, Dr.
- Email: yangxing2017@bjmu.edu.cn
- Phone: +861083572928
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.